IL248745B - (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza - Google Patents

(s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza

Info

Publication number
IL248745B
IL248745B IL248745A IL24874516A IL248745B IL 248745 B IL248745 B IL 248745B IL 248745 A IL248745 A IL 248745A IL 24874516 A IL24874516 A IL 24874516A IL 248745 B IL248745 B IL 248745B
Authority
IL
Israel
Prior art keywords
compound
cmin
plasma
htbz
per
Prior art date
Application number
IL248745A
Other languages
English (en)
Hebrew (he)
Other versions
IL248745A0 (en
Original Assignee
Neurocrine Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences filed Critical Neurocrine Biosciences
Publication of IL248745A0 publication Critical patent/IL248745A0/en
Publication of IL248745B publication Critical patent/IL248745B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL248745A 2014-05-06 2015-05-06 (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza IL248745B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
IL248745A0 IL248745A0 (en) 2017-01-31
IL248745B true IL248745B (en) 2022-07-01

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248745A IL248745B (en) 2014-05-06 2015-05-06 (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3139925B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20200133003A (enExample)
CN (3) CN106456629A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2976207T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20220025T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3936130T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000121A1 (en) 2015-10-30 2019-10-04 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3606529A1 (en) * 2017-04-01 2020-02-12 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US20200276184A1 (en) 2017-09-21 2020-09-03 Neurocrine Biosciences, Inc. High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
JP2021503009A (ja) * 2017-11-08 2021-02-04 フォアシー ファーマシューティカルズ シーオー．，リミテッド ジヒドロテトラベナジンのエステル
CN110621674B (zh) 2017-12-26 2022-03-29 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto
JP2021528481A (ja) 2018-08-15 2021-10-21 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２阻害剤を投与するための方法
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
JOP20210274A1 (ar) * 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
SI3061760T1 (en) 2008-09-18 2018-04-30 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
JP6718376B2 (ja) * 2014-02-07 2020-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, NEUROCRINE ANNOUNCES PHASE IIB RESULTS OF VMAT2 INHIBITOR NBI-98854 FOR TREATMENT OF TARDIVE DYSKINESIA, 9 September 2013 (2013-09-09) *

Also Published As

Publication number Publication date
RS65359B1 (sr) 2024-04-30
CA2947736C (en) 2023-04-18
JP2017514850A (ja) 2017-06-08
AU2015256012A1 (en) 2016-11-24
RU2016147523A (ru) 2018-06-08
MX387625B (es) 2025-03-18
HUE057839T2 (hu) 2022-06-28
EP4389227A2 (en) 2024-06-26
EP3936130A1 (en) 2022-01-12
RS62782B1 (sr) 2022-01-31
KR20220140647A (ko) 2022-10-18
PL3139925T3 (pl) 2022-03-21
RU2016147523A3 (enExample) 2018-12-28
ES2904526T3 (es) 2022-04-05
CN106456629A (zh) 2017-02-22
PT3139925T (pt) 2022-01-26
EP3936130B1 (en) 2024-02-14
MX2016014429A (es) 2017-04-06
HRP20240459T1 (hr) 2024-06-21
JP2021191799A (ja) 2021-12-16
FI3936130T3 (fi) 2024-04-23
CA2947736A1 (en) 2015-11-12
JP2024153782A (ja) 2024-10-29
EP4389227A3 (en) 2024-09-04
HUE066361T2 (hu) 2024-07-28
JP2019218407A (ja) 2019-12-26
KR20250029267A (ko) 2025-03-04
SI3139925T1 (sl) 2022-04-29
AU2015256012B2 (en) 2020-07-23
IL248745A0 (en) 2017-01-31
PT3936130T (pt) 2024-04-17
US20170071932A1 (en) 2017-03-16
PL3936130T3 (pl) 2024-06-10
JP6635945B2 (ja) 2020-01-29
SI3936130T1 (sl) 2024-05-31
SMT202200193T1 (it) 2022-07-21
CY1125058T1 (el) 2023-06-09
US20210196702A1 (en) 2021-07-01
RU2753740C2 (ru) 2021-08-23
ES2976207T3 (es) 2024-07-26
US20200101063A1 (en) 2020-04-02
DK3936130T3 (da) 2024-03-25
EP3139925A1 (en) 2017-03-15
LT3936130T (lt) 2024-04-25
CN112741836A (zh) 2021-05-04
KR20240011255A (ko) 2024-01-25
KR20160147044A (ko) 2016-12-21
LT3139925T (lt) 2022-01-25
DK3139925T3 (da) 2021-12-20
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
WO2015171802A1 (en) 2015-11-12
CN112741835A (zh) 2021-05-04
HRP20220025T1 (hr) 2022-04-01
NZ725826A (en) 2023-05-26
KR20200133003A (ko) 2020-11-25

Similar Documents

Publication Publication Date Title
IL248745B (en) (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza
US20220071949A1 (en) Combinations of cannabinoids and n-acylethanolamines
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
CA2787173C (en) Methods and compositions for improved nerve conduction velocity
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
EP4523748A2 (en) Treatment of pain and vasoconstriction
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
AU2008284364A1 (en) Use of phosphatases to treat neuroblastomas and medulloblastomas
TN2020000161A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP1397138B1 (de) WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE
JP2003176240A (ja) ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法
WO2023141334A3 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
CN104173332A (zh) 银杏内酯类化合物的新用途
US20060167026A1 (en) Antipsychotic molecular-targeting epithelial growth factor receptor
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
JP2006508958A (ja) 抗癌剤により誘発される末梢神経障害を予防および／または処置するための医薬品
MY205498A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
WO2021022058A3 (en) Antiarrhythmic formulation
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
EP2265267A1 (en) Compositions comprising n-halogenated or n, n-dihalogenated amine for treatment and prophylaxis of bronchopulmonary infections
WO2018057624A4 (en) Methods and compositions for stimulation and enhancement of regeneration of tissues
AU2004233564A1 (en) Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
WO2024073328A3 (en) Vanoxerine for use in the treatment of brain cancer, breast cancer, pancreatic cancer and lung cancer
HK40085288A (en) Combinations of cannabinoids and n-acylethanolamines
AU2008200878A1 (en) Use of a topical medicament comprising riluzole